The expert panel discussed and agreed upon the need or a simple, regional, electronic, prospective breast cancer registry for recording patient demographic and tumor biological characteristics, type of treatment, line of treatment, and details of disease progression, to help understand clinical practice patterns and the commitment of clinicians to optimizing the management of HR + HER2 − mBC in various regions. The gene discussed is ERBB2; the disease is breast carcinoma.